Sutro Biopharma (STRO) Liabilities and Shareholders Equity (2017 - 2025)

Sutro Biopharma's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $173.8 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 55.11% year-over-year to $173.8 million; the TTM figure through Dec 2025 stood at $967.3 million (down 44.14% YoY), while the FY2025 annual figure was $173.8 million, down 55.11% from the prior year.
• Liabilities and Shareholders Equity came in at $173.8 million for Q4 2025 at Sutro Biopharma, down from $209.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $489.0 million in Q2 2024 to a low of $173.8 million in Q4 2025.
• A 5-year average of $367.6 million and a median of $378.5 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 133.0% in 2021 and sank 55.11% in 2025, its largest moves.
• Sutro Biopharma's Liabilities and Shareholders Equity stood at $341.4 million in 2021, then advanced by 19.2% to $406.9 million in 2022, then advanced by 15.68% to $470.7 million in 2023, then slipped by 17.74% to $387.2 million in 2024, then tumbled by 55.11% to $173.8 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $173.8 million, $209.7 million, and $262.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison